What is Prolocor?
Prolocor operates at the intersection of biotechnology and precision diagnostics, focusing on the complex management of cardiovascular disease. The company's core innovation lies in its ability to quantify specific platelet markers, which serves as a vital tool for assessing patient risk profiles. By addressing the unmet need for personalized treatment strategies, Prolocor empowers healthcare providers to make more informed, data-driven decisions. This approach not only enhances the standard of care but also aligns with the broader industry shift toward targeted, patient-centric medical interventions. As a key player in the diagnostic sector, Prolocor is bridging the gap between laboratory research and clinical application, ensuring that complex cardiovascular conditions are managed with greater accuracy and efficacy.
How much funding has Prolocor raised?
Prolocor has raised a total of $4.9M across 2 funding rounds:
Angel/Seed
$3.2M
Debt
$1.7M
Angel/Seed (2022): $3.2M with participation from Green Park & Golf Ventures and Labcorp
Debt (2024): $1.7M led by Labcorp and Green Park & Golf Ventures
Key Investors in Prolocor
Green Park & Golf Ventures
A Dallas-based venture capital firm with over 60 years of operational experience, specializing in medical-related start-ups and providing strategic solutions to innovative healthcare teams.
Labcorp
A global laboratory services leader providing vital diagnostic information to hospitals, pharmaceutical companies, and researchers to facilitate confident clinical decision-making.
What's next for Prolocor?
With the recent capital injection, Prolocor is poised to scale its operational capabilities and refine its diagnostic pipeline. The strategic focus will likely center on expanding clinical validation studies and navigating the regulatory pathways necessary for broader market adoption. Given the involvement of major industry players like Labcorp, the company is uniquely positioned to leverage existing diagnostic infrastructure to expedite the commercialization of its platelet-based testing technology. Future growth will be defined by the successful integration of these diagnostic tools into standard clinical workflows, ultimately aiming to reduce the incidence of adverse cardiovascular events through early and precise intervention. The company remains committed to its mission of transforming cardiovascular risk management through scientific rigor and technological innovation.
See full Prolocor company page
